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Abstract
Purpose The treatment of large bone defects represents a sig-
nificant challenge for orthopaedic surgeons. In recent years,
biologic agents have also been used to further improve bone
healing. Among these, platelet-rich plasma (PRP) is the most
exploited strategy. The aim of the present study was to sys-
tematically review the available literature to identify: 1) pre-
clinical in-vivo results supporting the rational of PRP use for
bone healing; 2) evidence from the clinical practice on the
actual clinical benefit of PRP for the treatment of fractures
and complications such as delayed unions and non-unions.
Methods A systematic review of the literature was performed
on the application of PRP in bone healing, using the following
inclusion criteria: pre-clinical and clinical reports of any level
of evidence, written in English language, published in the last
20 years (1996–2016), on the use of PRP to stimulate long-
bone defect treatment, with focus on fracture and delayed/
non-unions healing.
Results The search in the Pubmed database identified 64 arti-
cles eligible for inclusion: 45 were preclinical in-vivo studies
and 19 were clinical studies. Despite the fact that the overall
pre-clinical results seem to support the benefit of PRP in
91.1 % of the studies, a more in depth analysis underlined a
lower success rate, with a positive outcome of 84.4 % in terms
of histological analysis, and even lower values considering
radiological and biomechanical results (75.0 % and 72.7 %
positive outcome respectively). This was also mirrored in the
clinical literature, where the real benefit of PRP use to treat
fractures and non-unions is still under debate.
Conclusion Overall, the available literature presents major
limitations in terms of low quality and extreme heterogeneity,
which hamper the possibility to optimize PRP treatment and
translate it into a real clinical benefit despite positive preclin-
ical findings on its biological potential to favour bone healing.
Keywords Bone defect . Bone healing . Fracture . Growth
factors . Non-union . PRP
Introduction
The treatment of large bone defects represents a significant clin-
ical challenge for orthopaedic surgeons [1, 2]. The well-
orchestrated regenerative ability of bone to heal is hampered,
in the case of complex defects, by the lack of a template for
regeneration and, eventually, it requires surgical intervention
[3]. Autografts and allografts are considered to be the major
bone substitutes, however they each have their own limitations
regarding availability, donor site morbidity and chronic pain,
leading to not always optimal results [4]. In order to overcome
these issues, several bone substitute materials have been devel-
oped and applied in the clinical practice [5, 6]. To further im-
prove the success rates, co-adjuvant agents have also been pro-
posed, which may enhance implant osseointegration potential
and restore bone tissue function [7]. Among these, growth fac-
tors (GFs) are expressed during different phases of tissue healing
and may represent a key element in promoting tissue regenera-
tion [8]. In fact, GFs delivered through orthopaedic devices have
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been reported to enhance osteoblastic activity and favour im-
plant integration [9, 10].
Platelet-rich plasma (PRP) is emerging as a powerful tool for
tissue healing, thanks to the many GFs contained in
platelet alpha-granules. PRP is defined as a blood derivative,
where the platelets concentration is above the baseline levels,
thus providing a large number of bioactive molecules in physio-
logic proportions [11]. Activated platelets can release more than
300 molecules that are responsible for the coordination of nu-
merous cell-cell and cell-extracellular matrix (ECM) interactions
[12]. The evidence for PRP osteogenic potential has been sug-
gested by several in vitro studies, i.e. PRP addition in culture
medium promoted the proliferation and differentiation of human
mesenchymal stem cells (MSCs) [13, 14], and the effect of PRP
on osteogenic differentiation was also seen on human adipose
derived stem cells (ADSCs) [15]. Furthermore, PRP can improve
cell chemokinesis and chemotaxis through cytoskeleton reorga-
nization and accelerate cell migration, thus influencing osteoblast
like cells mobility [16]. Finally, anti-microbial effects have been
suggested [17, 18], which are highly desirable in relation to a
surgical bone application. However, besides the beneficial role in
terms of proliferation and differentiation, as well as cell migration
and protection towards microbial contamination, in-vitro studies
have also shown controversial results on PRP potential to favour
bone healing [19–21].
Thus, the aim of this study was to systematically review the
available literature to identify both preclinical in-vivo results
supporting the rational of PRP use for bone healing, and the
evidence from the orthopaedics practice on the actual clinical
benefit of PRP for the treatment of bone disorders.
Materials and methods
A systematic review of the literature was performed on the use
of PRP in both pre-clinical in-vivo setting and clinical setting
for the treatment of fractures and delayed unions/non-unions.
The search was conducted on the PubMed database on August
1st, 2016 using the following string: (PRP OR platelet-rich
plasma OR plasma rich in growth factors OR platelet derived
growth factor OR platelet derived OR platelet gel OR platelet
concentrate OR PRF OR platelet rich fibrin OR platelet rich
membrane OR ACP OR autologous conditioned plasma OR
PRGF OR platelet lysate) AND (fracture OR trauma OR trau-
matic OR non union OR mal union OR post-traumatic OR
pseudoarthrosis OR delayed union OR bone defect).
The screening process and analysis were conducted separately
by two independent observers (BDM and GS). First, the articles
were screened by title and abstract, using the following inclusion
criteria: pre-clinical and clinical reports of any level of evidence,
written in English language, published in the last 20 years (1996–
2016), on the use of PRP to stimulate long-bone defect treatment,
with focus on fracture and delayed/non-unions healing.
Exclusion criteria were articles written in other languages, re-
views, case reports or case series with less than ten patients
included, or studies analysing other applications of PRP in bone
pathology. In the second step, the full texts of the selected articles
were screened, with further exclusions according to the previous-
ly described criteria. Reference lists from the selected papers
were also screened. A flowchart of the systematic review process
is provided in Fig. 1. Relevant data were then extracted and
collected, with the consensus of the two observers, in a database
including pertinent information (type of study, number of cases,
follow-up, PRP preparation, cytology and application modality,
type of surgical treatment or animal model used, type of bone or
other materials applied, type of evaluation and results) to be
analysed for the purposes of the present manuscript.
Results
In total 3160 articles were screened and 64 articles were found
to be eligible for inclusion in the present review. Among these,
45 were pre-clinical in-vivo studies [1, 2, 4, 22–63] and 19
were clinical studies [64–83] (Fig. 1). The trend of publication
of pre-clinical and clinical trials over years has been reported




Of the 45 identified studies (Table 1), 20 (44.4 %) used a
rabbit model, while other animals were used in a smaller num-
ber of studies, i.e. rat in eight studies (17.8 %), sheep in seven
studies (15.6 %), dog in four studies (8.9 %), pig in four
studies (8.9 %) and goat in two studies (4.4 %). With regard
to defect type, bone sites were tibia in 16 studies (35.6 %)
(four segmental, 14 cylindrical defects), femur in 14 studies
(31.1 %) (two segmental, eight cylindrical defects, four frac-
tures), radius in ten studies (22.2 %) (nine segmental, one
fracture), fibula in 1 study (2.2 %) (one fracture), ulna in three
studies (6.7 %) (three segmental defects) and metatarsus in
one study (2.2 %) (one segmental defects).
With regard to the delivery mode, 3/45 studies delivered
PRP through percutaneous injection while the remaining stud-
ies used the surgical approach to apply PRP either alone or in
combination with other materials. Only one paper described
the combination of percutaneous PRP injection and surgical
PRP delivery with biomaterial. Besides seven articles (16 %)
documenting the effect of PRP alone, most of the studies (38
papers, 84 %) analysed the effect of PRP with other materials:
20 studies (53 %) reported the use of three dimensional scaf-
folds, nine (23.5 %) with auto (n = 5) / allo (n = 3) / xenografts
(n = 1) and nine (23.5 %) with powders/granules/pastes.
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Finally, with regard to other biological augmentations, 11 pa-
pers (24.4 %) reported the use of MSCs as a co-adjuvant
osteogenic factor in their studies. BMSCs was the favourite
cell source, used in eight papers, followed by bone marrow
concentrate (BMC) in two articles, and BMSCs vs. ADSCs
were reported in one article.
PRP preparation
Platelet count was reported in studies 32/45 (71 %) with het-
erogeneous platelet concentration. However, all showed sig-
nificantly higher levels of platelets than in whole peripheral
blood, ranging from 1.1 x to 10.1 x. Sixteen out of 45 papers
Fig. 1 PRISMA flowchart of the
papers’ selection process
Fig. 2 Pre-clinical and clinical
studies published over time
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reported information about leukocytes content in PRP, nine of
which described the use of leukocyte-rich PRP and seven of
leukocyte-poor PRP. Only one paper out of 45 reported fibrin-
ogen content. Fourteen studies analysed PRP for GFs, which
included TGF-β1 (in 14), PDGF (in ten), VEGF (in four),
bFGF (in one), SDF-1 (in one), p-selectine (in one), BMP-2
(in one), IL-1 (in one) and EGF (in one).
Thirty-two out of 45 papers (71 %) reported information
about the use of fresh or frozen PRP: 26 were fresh and six
frozen; while 42 (93.3 %) papers reported the type of PRP in
terms of autologous (in 24), allogeneic (in 15), and xenoge-
neic (in three) origin. Finally, PRP activationmodality was not
reported in 12 studies; among studies where this was specified
(33 papers, 73.3 %), 20 (60.6 %) reported a combination of
CaCl2 and thrombin, nine (27.3 %) used CaCl2 alone, two
(6.1 %) thrombin alone, one (3 %) calcium gluconate, one
(3 %) calcium borogluconate and one (3 %) batroxobin.
Pre-clinical findings
Overall positive results were shown in 41 studies (91 %),
while three studies (7 %) showed the same results as control
and one study (2 %) showed negative effects of PRP use. In
particular, among the 20 studies reporting the use of PRP with
scaffolds (hydroxyapatite alone or in combination with colla-
gen was the most frequent material used), 18 showed positive
results; among the nine papers using bone grafts, all reported
good results. Among the nine studies on PRP with powder/
granules, eight showed a good outcome. Finally, among the
seven studies where PRP was used alone, six reported good
results while one study using PRP injections failed to show
significant effects. Finally, the use ofMSCs always provided a
benefit, with PRP further increasing the outcome in all 11
studies.
Further analyses have been performed according to the
results of each specific evaluation performed. The histological
outcome has been reported in 45 papers, with 38 (84.4 %)
showing significant improvement in bone healing. The radio-
graphic outcome was reported in 32/45 papers; among these
studies 24 (75.0 %) showed significant bone consolidation.
The micro-computed tomography (CT) outcome was reported
in 11 papers and significant bone area formation was reported
in nine (81.8 %) studies. DEXA analysis was reported only in
three studies, with good results in favour of PRP in all papers.
Finally, biomechanical tests in regard to torsion, torque and
bone strength, were performed in ten papers and seven (70 %)
of these studies documented significantly better biomechani-
cal properties.
Clinical studies
A total of 19 clinical trials were found to be eligible for inclu-
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management [64–72] whereas ten focused on fracture compli-
cations [73–83] (i.e. delayed unions or non-unions; Table 2).
Treatment of fractures
Eight out of nine studies were RCTs and one was a retrospec-
tive comparative trial [64]. Three studies aimed at understand-
ing the role of PRP in stimulating healing after iatrogenic
fractures: two trials in opening-wedge high tibial osteotomy
(HTO) [65, 66] and one in tibial distraction osteogenesis for
limb lengthening [67]. The other six trials focused on dispa-
rate traumatic injuries: two papers on hip fractures [68, 69],
one paper on calcaneus fractures [70], one (the retrospective
comparative trial) on complex bimalleolar fractures [64], one
on tibial pilon fractures [71] and one on intra-articular distal
radial fractures [72]. With regard to the application strategies,
PRP was locally applied during surgery in eight studies,
whereas in one case a delayed PRP injection was applied
(3–6 weeks after primary surgery) [70]. PRP was leukocyte-
rich in five papers and leukocyte-depleted in two studies,
while in two papers authors did not provide specific details
about the PRP formulation adopted. In six trials PRP was
associated to other Baugmentation strategies^, such as MSCs
and/or bone graft (Table 2).
Overall, eight out of nine papers reported radiologic out-
comes: six of them revealed better results with PRP, one found
no difference, whereas one paper documented worse radiolog-
ic results with the biologic augmentation. Clinical outcomes
were reported in only five papers, i.e. functional subjective
scores and/or objective measurements and/or complications
after PRP treatment: in three cases PRP did not provide any
beneficial contribution, whereas in the remaining two studies
it contributed to a superior clinical outcome. Finally, only one
trial documented histomorphometric results, showing that the
addition of PRP to bone chips, even more if combined with
BMC augmentation, was able to promote a superior healing of
the high tibial osteotomy gap site (Table 2).
Treatment of delayed unions/non unions
Out of the ten studies (11 papers in total) on the application of
PRP to manage delayed unions or non-unions [73–83], four
used a minimally invasive approach through percutaneous
PRP injections, six studies used PRP as topical enhancer dur-
ing revision surgery, whereas one study reported results of
both treatment approaches (Table 2). Only one trial (which
was the object of two different publications, one reporting
the preliminary results and the other reporting the complete
data) was a RCT [73, 74], whereas all the others were case
series. In four studies PRP was used together with other aug-
mentation strategies (bone graft or synthetic bone). PRP was
leukocyte-rich in two studies and leukocyte-depleted in three
studies, while in five trials authors did not provide specific
details about the PRP formulation adopted (Table 2).
All but one [75] study considered patients affected by de-
layed union/non-union in different anatomical districts pooled
together (mainly humerus, femur and tibia, which are the most
common sites for this kind of complication), thus reducing the
homogeneity of the cohorts of patients. With regard to the
outcome, two case series (where PRP was injected at the site
of non-union or delayed union) failed to documented a bene-
ficial effect of the biological stimulation [76, 77]. The other
reports suggested instead a positive role of PRP, although the
only RCT documented a clear advantage of bone
morphogeneic protein 7 (BMP-7) over PRP in stimulating
bone healing (Table 2) [73, 74].
Discussion
This systematic research of the literature documented a grow-
ing interest on PRP use for bone disorders, with an increasing
number of papers published over time which show a complex
scenery and more controversial results than previously
thought.
In fact, while basic science suggests several favourable
potential effects of PRP for bone healing, and platelet concen-
trates have also been successfully used in other medical fields
to enhance bone and soft tissue regeneration [5, 84–86], the
evidence on its real benefit is questionable. The first phase of
the literature analysis focused on preclinical in-vivo evidence,
which should allow us to understand potential and indications
for PRP use. This systematic review documented 45 papers
reporting heterogeneous models both in terms of animal mod-
el and defect type chosen. This is an important factor to con-
sider in terms of results transferability to the clinical field. In
fact, although several models are appropriate for the evalua-
tion of bone regeneration, not all of them closely reproduce
human tissue characteristics. Chosen models should present
physiological and pathophysiological analogies to favour re-
sults transferability: for this reason larger models more closely
resemble the human condition [87]. For example, pig models
present bone features similar to humans in terms of mineral
density, concentration and healing capacity, with a 1.2 to
1.5 mm per day growth rate, similar to bone regeneration
capacity in humans [88]. Among the studies found in this
systematic review, only four chose the pig model, while the
majority adopted smaller models with rabbits or even rats.
Moreover, these animal models analysed surgically-created
acute lesions which were treated immediately, oppositely to
what happens in the clinical practice. Despite the inherent
limits of these models in terms of transferability to humans,
these studies still showed overall promising findings, with a
positive outcome documented in 91.1 % of the papers.
However, a more in depth analysis shed some doubts on the
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real potential of PRP. In fact, looking at the specific evalua-
tions performed, the percentage of success decreased. While
histological analysis showed an improvement in 84.4 % of the
experiments, imaging analysis showed a lower success, with a
75.0 % success rate documented through radiological analy-
sis. Moreover, the higher quality of the regenerated tissue
should lead to a stronger tissue, but biomechanical analysis
could prove superior results related to PRP use only in 72.7 %
of the studies. This is an important factor, because it raises
some caution on the interpretation of the positive results of
several studies based on different and more successful out-
comes. An improved regeneration should allow for higher
biomechanical properties to be considered significant, other-
wise the real usefulness of this biological augmentation re-
mains questionable. Besides the lack of biomechanical evalu-
ations, performed only in a minority of preclinical studies,
other aspects hinder the understanding of PRP potential.
These lie in the limitations of the current preclinical literature,
in terms of extreme heterogeneity of the published studies as
well as often poor study quality.
Most of the studies fail to report key aspects that may
influence the final outcome and hinder a correct interpretation
of the results: platelet concentrations, leukocyte components,
activation modality etc. are often overlooked. Even though
several products with a wide range of cell concentration are
included in the PRP family [89], the number and type of cells
applied is not a secondary aspect. A platelet concentration of
approximately (1,000,000/μl) has been linked to positive bio-
logical effects in bone regeneration by Weibrich et al. [90].
Chen et al. [60] showed how a medium concentration of PRP
(2.65 ± 0.2 × 109/ml) induced osteogenic differentiation of
BMSCs and improved fracture healing, while a high concen-
tration of PRP (8.21 ± 0.4 × 109/ml) inhibited osteogenic dif-
ferentiation of BMSCs and delayed callus remodelling in a rat
femoral osteotomy. Other than the importance of platelet num-
ber, Perut et al. [21] underlined the contribution of other cells
to the overall effect: leukocyte-rich PRP induced significantly
higher proliferation of BMSCs compared to leukocyte-
depleted PRP. Moreover, other studies emphasized the impor-
tance of further aspects related to PRP, such as storage or
activation modality that, together with the autologous or allo-
geneic nature, the characteristics of the donor and the prepa-
ration method etc., may influence the molecules released and
the biological results of platelet concentrates [88, 91, 92]. PRP
effects may also depend on the treatment condition, i.e. the
application modality, in particular in terms of injective or sur-
gical delivery (a more solid state with more fibrin may imply a
different release of the GFs from the fibrin net [93]), and even
more with combined augmentation procedures. Preclinical
studies are highly heterogeneous in terms of materials com-
bined with PRP, which has been suggested to influence cell-
signalling molecules that promote osteogenesis [20] and, in
the end, the success rate [5]. Moreover, PRP has also been
combined with MSCs: while overall results of the combined
treatment seemed positive, the independent contribution of
PRP remains questionable.
All these factors contribute to the complexity of the pre-
clinical findings and leave many open questions on the opti-
mization and transferability of PRP potential for humans use.
Overall clinical findings confirm the preclinical scenery. The
lack of clear indications on the best way to apply platelet
concentrates is reflected by an extreme heterogeneity in terms
of PRP preparations, as well as in targets and delivery
methods. Moreover, the quality of the studies is limited: as
for the preclinical field, many key parameters are omitted,
the study design is poor and even for randomized trial low
patients numbers and the presence of concomitant confound-
ing factors hinder the possibility to have clear results. This is a
key aspect since a tendency to report better results with lower
quality studies compared to more scientific robust ones has
already been reported [5]. Finally, it has to also be emphasized
for clinical studies that not all positive results may be clinical-
ly significant. In fact, the rational of a biological augmentation
is to favour a faster recovery. Earlier weight bearing and mo-
bilization may lead to fewer adhesions, higher postoperative
range of motion and earlier return to physical activity [88]. To
this aim, positive histological or imaging findings may be
insufficient if not coupled by a significant increase in biome-
chanical quality of bone. The analysis of the clinical studies in
terms of documented clinical benefit shows an even lower
outcome than what is suggested by imaging findings, which
further questions the real benefit provided by PRP use to fa-
vour bone regeneration in the clinical practice.
Thus, while positive findings have been suggested by the
pre-clinical literature, a more in depth evaluation shed some
doubts on the real role of PRP, which are confirmed by the
limited benefits documented in the human experience.
Currently, there is no evidence to support the routine use of
PRP to enhance bone healing. Therefore, until trials with high
methodological quality will allow the optimization of its bio-
logical potential and clearly prove results and indications,
PRP use should be restricted to controlled studies investigat-
ing its real benefit for the treatment of bone pathologies.
Conclusions
This systematic research of the literature documented a grow-
ing interest on PRP use for bone disorders. While the overall
pre-clinical results seem to support the benefit of PRP in
91.1 % of the studies, a more in depth analysis underlines a
lower success rate, with a positive outcome of 84.4 % in terms
of histological analysis, and even lower when considering
radiological and biomechanical analysis, 75.0 % and
72.7 %, respectively. This is reflected by controversial find-
ings also documented in the clinical literature, where the real
International Orthopaedics (SICOT) (2017) 41:221–237 233
benefit of PRP use to treat fractures and non-unions is ques-
tionable. Overall, the available literature presents major limi-
tations in terms of low quality and extreme heterogeneity,
which hamper the possibility to optimize PRP treatment and
translate positive preclinical findings on its biological poten-
tial to favour bone healing into a real clinical benefit.
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